Etonogestrel implant - Merck & Co
Alternative Names: 3-Keto-desogestrel; 3-Keto-DOG; 3-Oxodesogestrel; Etonogestrel extended-release subdermal implant; Implanon; Implanon NXT; MK-8415; NEXPLANON; Nexplanon; Org 32222; ORG-3236; SCH900415Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Organon
- Developer Merck & Co; Organon; Pharmaco (NZ); Schering-Plough
- Class Hormonal contraceptives; Norpregnanes; Phenanthrenes; Progesterone congeners; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pregnancy
Most Recent Events
- 22 Apr 2021 Merck completes a phase I trial in Pregnancy (Prevention) in USA (Intradermal) (NCT03335163)
- 19 Nov 2020 Phase-III clinical trials in Pregnancy (Prevention) in Puerto Rico (Intradermal) (NCT04626596)
- 19 Nov 2020 Merck initiates enrolment in the phase III trial for Pregnancy (Prevention) in USA (Intradermal) (NCT04626596)